DOCSLIB.ORG

Proquest Dissertations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proquest Dissertations Human liver glycolate oxidase Gene identification and protein studies Emma Louise Wiiliams UCL A thesis submitted for the degree of Doctor of Philosophy University College London Abstract Glycolate oxidase (GO) is a peroxisomal flavoenzyme which catalyses the oxidation of short chain a-hydroxy acids, notably glycolate. The reaction product, glyoxylate, is an oxalate precursor and GO is thus of potential interest for its role in the pathogenesis of the primary hyperoxalurias. The project aims were to identify human GO, characterise the kinetics and substrate specificity of the enzyme and establish methods for the analysis of relevant metabolic pathways in vitro. The gene for human GO was cloned from liver and expressed in bacterial cells. The cDNA is 1128 bp in length and has a 1113 bp open reading frame encoding a 372 amino acid protein. The genomic sequence comprises eight exons and spans -57 kb of chromosome 20pl2. Recombinant human GO protein shares 53% and 89% sequence similarity to GO from spinach and rat respectively, shows a-hydroxy acid oxidase activity in vitro and has been purified to homogeneity. Polyclonal anti-GO antibody detects a band of 43 kDa in human liver and, consistent with northern blot analysis, expression is not detected in other tissues including kidney and leucocytes. Kinetic analysis with a range of a-hydroxy acids indicates GO has highest affinity for glycolate as substrate (K^ = 0.54 mM) and 10 fold less affinity for glyoxylate (K^,= 5.1 mM). Site directed mutagenesis of active site residues demonstrates the importance of chain length for substrate affinity. Thus mutation of a Trp residue, conserved between spinach and human GO to a less bulky amino acid, permits the catalysis of longer chain length a-hydroxy acids. HPLC methods were developed for the separation and quantitation of glyoxylate, hydroxypyruvate and pyruvate, enabling analysis of metabolites produced by GO and neighboring enzymes in the metabolic pathway. These assays will be invaluable for future studies in which the pathways of glyoxylate metabolism are constructed in vitro. Abbreviations Enzymes and EC numbers: AGT alanine:glyoxylate aminotransferase (EC 2.6.1.44) ALDH aldehyde dehydrogenase (EC 1.2.1.21) CL 2-oxoglutarate:glyoxylate carboligase (EC 4.1.3.15) DAO D-amino acid oxidase (EC 1.4.3.3) D-GDH D-glycerate dehydrogenase (EC 1.1.1.29) DGK D-glycerate kinase (EC 2.7.1.31) FCBz flavocytochrome hi (EC 1.1.2.3) GDH glycolate dehydrogenase (EC 1.1.99.14) GGT glutamate:glyoxylate aminotransferase (EC 2.6.1.4) GO glycolate oxidase (EC 1.1.3.15) GR glyoxylate reductase (EC 1.1.1.79) HAO A hydroxy acid oxidase type A (EC 1.1.3.15) HAO B hydroxy acid oxidase type B (EC 1.1.3.15) HPD hydroxypyruvate dehydrogenase (EC 4.1.1.40) HPR hydroxypyruvate reductase (EC 1.1.1.79) LDH lactate dehydrogenase (EC 1.1.1.27) LMO lactate mono-oxygenase (EC 1.13.12.4) MDH mandelate dehydrogenase (EC 1.1.2.3) PGDH phosphoglycerate dehydrogenase (EC 1.1.1.95) PGI phosphoglycerate isomerase (EC 5.4.2.1 ) PSA phosphoserine transaminase (EC 2.6.1.52) PSP phosphoserine phosphatase (EC 3.1.3.3) RUBISCO ribulose bisphosphate carboxylase/oxygenase (EC 4.1.1.39) SPT serineipyruvate aminotransferase (EC 2.6.1.51) XAO xanthine oxidase (EC 1.1.3.22) General abbreviations: cDNA complementary DNA DNA deoxyribonucleic acid dNTP deoxynucleoside triphosphate EDTA ethylenediaminetetra-acetic acid FMN flavin mononucleotide HPLC high performance liquid chromatography mRNA messenger RNA NAD+ p-Nicotinamide adenine dinucleotide NADH p-Nicotinamide adenine dinucleotide, reduced form NADP+ p-Nicotinamide adenine dinucleotide phosphate NADPH p-Nicotinamide adenine dinucleotide phosphate, reduced form OPD o-phenylenediamine PHI primary hyperoxaluria type 1 PH2 primary hyperoxaluria type 2 PHZ phenylhydrazine hydrochloride PTS peroxisomal targeting signal PAGE polyacrylamide gel electrophoresis RNA ribonucleic acid RT-PCR Reverse transcriptase polymerase chain reaction SDS sodium dodecyl sulphate Table of Contents Chapter Index Tit l e ....................................................................................................................................................... 1 A bstract ...............................................................................................................................................2 A bbreviations ....................................................................................................................................4 Table of C o n te n t s ........................................................................................................................... 7 CHAPTER INDEX.................................................................................................................................. 7 LIST OF FIGURES.................................................................................................................................10 LIST OF TABLES..................................................................................................................................13 A cknowledgements .......................................................................................................................14 1.0 C h a pter O ne - I ntroduction ...........................................................................................15 1.1 Ox a l a t e .................................................................................................................................... 16 1.1.1 Dietary intake and absorption o f oxalate .................................................................... 17 1.1.2 Renal handling o f oxalate ................................................................................................18 1.2 Endogenous Oxalate P roduction .................................................................................20 1.2.1 Glyoxylate synthesis .......................................................................................................... 21 1.2.2 Glyoxylate utilisation ........................................................................................................27 1.3 H yperoxaluria ...................................................................................................................... 34 1.4 Secondary H yperoxaluria .............................................................................................. 35 1.5 P rimary H yperoxaluria .................................................................................................... 37 1.5.1 Primary hyperoxaluria type 1 ........................................................................................ 37 1.5.2 Primary hyperoxaluria type 2 ........................................................................................ 43 1.5.2 The treatment o f primary hyperoxaluria ...................................................................... 48 1.5.4 Atypical hyperoxaluria .....................................................................................................51 1.6 G lycolate Oxid ase ..............................................................................................................53 1.6.1 GO in plants ........................................................................................................................56 1.6.2 GO in anim als .................................................................................................................... 57 2.0 C h a pter T w o - G enera l M e t h o d s ................................................................................59 2.1 Introduction ..........................................................................................................................60 2.2 M a ter ia ls ................................................................................................................................60 2.2.1 Chemicals .............................................................................................................................60 2.2.2 Buffers ...................................................................................................................................60 2.2.3 Bacterial media and antibiotics .....................................................................................63 2.3 M eth ods ....................................................................................................................................65 2.3.1 Isolation of human liver RNA ..........................................................................................65 2.3.2 Reverse transcriptase-polymerase chain reaction (RT-PCR) ................................ 65 2.3.3 TA cloning of PCR products ...........................................................................................66 2.3.4 Sequencing .......................................................................................................................... 67 2.3.5 Northern blot analysis ......................................................................................................68 2.3.6 Transfection intoBL21 competent cells ....................................................................... 68 2.3.7 Expression o f recombinant protein in BL21 cells .....................................................69 2.3.8 Protein SDS-PAGE ............................................................................................................69 2.3.9 Protein staining with Coomassie brilliant blue ..........................................................70 2.3.10
Load more

Recommended publications
  • Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations
    REVIEW OFFICIAL JOURNAL Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations www.hgvs.org Arunkanth Ankala,1∗ † Parag M. Tamhankar,2 † C. Alexander Valencia,3,4 Krishna K. Rayam,5 Manisha M. Kumar,5 and Madhuri R. Hegde1 1Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia; 2ICMR Genetic Research Center, National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India; 3Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 4Department of Pediatrics, University of Cincinnati Medical School, Cincinnati, Ohio; 5Department of Biosciences, CMR Institute of Management Studies, Bangalore, Karnataka, India Communicated by Arupa Ganguly Received 24 October 2013; accepted revised manuscript 16 September 2014. Published online 27 November 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22704 that include a lack of widespread awareness about genetic disorders in the general population and the scarcity of specialized medical ABSTRACT: South Asian Indians represent a sixth of the world’s population and are a racially, geographically, and professionals and affordable genetic tests. Seeking a molecular di- genetically diverse people. Their unique anthropological agnosis and understanding the risk estimates are critical to making structure, prevailing caste system, and ancient religious sound reproductive choices, especially in families with an affected practices have all impacted the genetic composition of most individual. Adding to this adversity is the absence of a properly func- of the current-day Indian population. With the evolving tioning social health care system and insufficient encouragement socio-religious and economic activities of the subsects and of individual health insurance by the government.
    [Show full text]
  • Oxalate Loading Test: a Screening Test for Steatorrhoea
    Gut: first published as 10.1136/gut.20.12.1089 on 1 December 1979. Downloaded from Gut, 1979, 20, 1089-1094 Oxalate loading test: a screening test for steatorrhoea D. S. RAMPTON', G. P. KASIDAS, G. ALAN ROSE, AND MARTIN SARNER2 From University College Hospital, London, St. Peter's Hospitals and Institute of Urology, London SUMMARY To investigate the possibility of measuring urinary oxalate output instead of faecal fat excretion as an outpatient screening test for steatorrhoea, we determined 24 hour urinary oxalate and five day faecal fat excretion before and during an oral load of sodium oxalate 600 mg daily (oxalate 4-44 mmol), in 32 patients with suspected malabsorption on a diet containing oxalate 30 mg (0-33 mmol), fat 50 g (180 mmol), and calcium 1 g (25 mmol). Nineteen patients proved to have steatorrhoea (mean faecal fat 62 mmol/24 h, range 19-186 mmol) of varying aetiologies. On the diet alone, urinary oxalate was raised in only nine of these patients (mean 0 25 mmol/24 h, range 0-08-059 mmol) (normal <0 20). By contrast, when the diet was supplemented with oral sodium oxalate, all 19 patients with steatorrhoea had hyperoxaluria (mean 0-91 mmol/24 h, range 046- 1P44 mmol) (normal <0-44). There was a significant positive linear relationship between urinary oxalate and faecal fat when the 32 patients were on the high oxalate intake (r=0*73, P <0.001), but not when they were on the low oxalate intake. Mean percentage absorption of orally administered oxalate was 58+09% (±1 SD) in normal subjects and 14-7+6-0% (P <0.002) in patients with steatorrhoea.
    [Show full text]
  • DISSERTATION PROTEOMIC PROFILING of the RAT RENAL PROXIMAL CONVOLUTED TUBULE in RESPONSE to CHRONIC METABOLIC ACIDOSIS Submitted
    DISSERTATION PROTEOMIC PROFILING OF THE RAT RENAL PROXIMAL CONVOLUTED TUBULE IN RESPONSE TO CHRONIC METABOLIC ACIDOSIS Submitted by Dana Marie Freund Department of Biochemistry and Molecular Biology In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Spring 2013 Doctoral Committee: Advisor: Norman Curthoys Co-Advisor: Jessica Prenni Jennifer Nyborg Olve Peersen Karen Dobos ABSTRACT PROTEOMIC PROFILING OF THE RAT RENAL PROXIMAL CONVOLUTED TUBULE IN RESPONSE TO CHRONIC METABOLIC ACIDOSIS The human kidneys contain more than one million glomeruli which filter nearly 200 liters of plasma per day. The proximal tubule is the segment of the nephron that immediately follows the glomeruli. This portion of the nephron contributes to fluid, electrolyte and nutrient homeostasis by reabsorbing 60-70% of the filtered water and NaCl and an even greater proportion of NaHCO3. The initial or convoluted portion of the proximal tubule reabsorbs nearly all of the nutrients in the glomerular filtrate and is the site of active secretion and many of the metabolic functions of the kidney. For example, the proximal convoluted tubule is the primary site of renal ammoniagenesis and gluconeogenesis, processes that are significantly activated during metabolic acidosis. Metabolic acidosis is a common clinical condition that is characterized by a decrease in blood pH and bicarbonate concentration. Metabolic acidosis also occurs frequently as a secondary complication, which adversely affects the outcome of patients with various life- threatening conditions. This type of acidosis can occur acutely, lasting for a few hours to a day, or as a chronic condition where acid-base balance is not fully restored.
    [Show full text]
  • Glycine Transaminase 1. Identification of The
    SAFETY DATA SHEET glycine transaminase Not for Private Therapeutic Use! 1. Identification of the Substance/preparation and of the company/undertaking 1.1 Identification of the Product: glycine transaminase (EXWM-2880) 1.2 Manufacture/Supplier Identification: Creative Enzymes 45-1 Ramsey Road Shirley, NY 11967, USA Tel: 1-631-562-8517 1-516-512-3133 Fax: 1-631-938-8127 E-mail: [email protected] Website: www.creative-enzymes.com 1.3 Relevant identified uses of the substance or mixture and uses advised against Identified uses: For research use only, not for human or veterinary use. 1.4 Emergency telephone number Emergency Phone #: +1-800-424-9300 (CHEMTREC Within USA and Canada) +1-703-527-3887 (CHEMTREC Outside USA and Canada) 2. Hazards Identification Physical/chemical hazards :n/a Human health hazards: Not specific hazard 3. EC No. / CAS No. EC No.:EC 2.6.1.4 CAS No.: 9032-99-9 4. First Aid Measures 4.1 Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention. 4.2 Ingestion: Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an Unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosentight clothing such as a collar, tie, belt or waistband. Ingestion: Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an Unconscious person. If large quantities of this material are swallowed, call a physician immediately.
    [Show full text]
  • Reactome | Metabolism of Amino Acids and Derivatives (R-HSA-71291)
    Metabolism of amino acids and derivatives D'Eustachio, P., Gopinathrao, G., Ito, S., Jassal, B., Jupe, S., Rush, MG., Stephan, R., Williams, MG., d'Ischia, M. European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University. The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 Inter- national (CC BY 4.0) License. For more information see our license. 06/08/2021 Introduction Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross- referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics research- ers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioin- formaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways. The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program). Literature references Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway ana- lysis: a high-performance in-memory approach. BMC bioinformatics, 18, 142.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Oxalic Acid Degradation by a Novel Fungal Oxalate Oxidase from Abortiporus Biennis Marcin Grąz1*, Kamila Rachwał2, Radosław Zan2 and Anna Jarosz-Wilkołazka1
    Vol. 63, No 3/2016 595–600 http://dx.doi.org/10.18388/abp.2016_1282 Regular paper Oxalic acid degradation by a novel fungal oxalate oxidase from Abortiporus biennis Marcin Grąz1*, Kamila Rachwał2, Radosław Zan2 and Anna Jarosz-Wilkołazka1 1Department of Biochemistry, Maria Curie-Skłodowska University, Lublin, Poland; 2Department of Genetics and Microbiology, Maria Curie-Skłodowska University, Lublin, Poland Oxalate oxidase was identified in mycelial extracts of a to formic acid and carbon dioxide (Mäkelä et al., 2002). basidiomycete Abortiporus biennis strain. Intracellular The degradation of oxalate via action of oxalate oxidase enzyme activity was detected only after prior lowering (EC 1.2.3.4), described in our study, is atypical for fun- of the pH value of the fungal cultures by using oxalic or gi and was found predominantly in higher plants. The hydrochloric acids. This enzyme was purified using size best characterised oxalate oxidase originates from cereal exclusion chromatography (Sephadex G-25) and ion-ex- plants (Dunwell, 2000). Currently, only three oxalate oxi- change chromatography (DEAE-Sepharose). This enzyme dases of basidiomycete fungi have been described - an exhibited optimum activity at pH 2 when incubated at enzyme from Tilletia contraversa (Vaisey et al., 1961), the 40°C, and the optimum temperature was established at best characterised so far enzyme from Ceriporiopsis subver- 60°C. Among the tested organic acids, this enzyme ex- mispora (Aguilar et al., 1999), and an enzyme produced by hibited specificity only towards oxalic acid. Molecular Abortiporus biennis (Grąz et al., 2009). The enzyme from mass was calculated as 58 kDa. The values of Km for oxa- C.
    [Show full text]
  • PROTEOMIC ANALYSIS of HUMAN URINARY EXOSOMES. Patricia
    ABSTRACT Title of Document: PROTEOMIC ANALYSIS OF HUMAN URINARY EXOSOMES. Patricia Amalia Gonzales Mancilla, Ph.D., 2009 Directed By: Associate Professor Nam Sun Wang, Department of Chemical and Biomolecular Engineering Exosomes originate as the internal vesicles of multivesicular bodies (MVBs) in cells. These small vesicles (40-100 nm) have been shown to be secreted by most cell types throughout the body. In the kidney, urinary exosomes are released to the urine by fusion of the outer membrane of the MVBs with the apical plasma membrane of renal tubular epithelia. Exosomes contain apical membrane and cytosolic proteins and can be isolated using differential centrifugation. The analysis of urinary exosomes provides a non- invasive means of acquiring information about the physiological or pathophysiological state of renal cells. The overall objective of this research was to develop methods and knowledge infrastructure for urinary proteomics. We proposed to conduct a proteomic analysis of human urinary exosomes. The first objective was to profile the proteome of human urinary exosomes using liquid chromatography-tandem spectrometry (LC- MS/MS) and specialized software for identification of peptide sequences from fragmentation spectra. We unambiguously identified 1132 proteins. In addition, the phosphoproteome of human urinary exosomes was profiled using the neutral loss scanning acquisition mode of LC-MS/MS. The phosphoproteomic profiling identified 19 phosphorylation sites corresponding to 14 phosphoproteins. The second objective was to analyze urinary exosomes samples isolated from patients with genetic mutations. Polyclonal antibodies were generated to recognize epitopes on the gene products of these genetic mutations, NKCC2 and MRP4. The potential usefulness of urinary exosome analysis was demonstrated using the well-defined renal tubulopathy, Bartter syndrome type I and using the single nucleotide polymorphism in the ABCC4 gene.
    [Show full text]
  • Glycine and Serine Inhibition of D-Glycerate Dehydrogenase and 3-Phosphoglycerate Dehydrogenase of Rat Brain
    Volume 17, number 1 FEBS LETTERS September 1971 GLYCINE AND SERINE INHIBITION OF D-GLYCERATE DEHYDROGENASE AND 3-PHOSPHOGLYCERATE DEHYDROGENASE OF RAT BRAIN M.L. UHR and M.K. SNEDDON Department of Physiology, Australian National University, Canberra, A.C. T. 2601, Australia Received 16 July 1971 1. Introduction 2. Materials and methods Glycine is probably a major inhibitory transmitter Barium phosphoglycerate and calcium DL-glycer- in the mammalian central nervous system [ 1,2] . ate purchased from Sigma Chemical Corporation, were Hence the metabolism and metabolic control of converted to sodium salts by passage through a glycine could be important for the efficient function- column of Dowex-SO(H?) and neutralization of the ing of nervous tissue, particularly of the spinal cord. emerging acids. Phosphoglycerate concentration was As glycine may be formed from serine by serine estimated by the method of Czok and Eckert [7]. hydroxymethylase (EC 2.1.2.1) [3] , enzymes neces- Glycerate was estimated by the method of Bartlett sary for the formation of serine from carbohydrate [8] with the concentration of chromotrophic acid sources could be important for the production and raised to 0.025% as recommended by Dawkins and regulation of glycine. Two major pathways of serine Dickens [9] . NAD was purchased from P-L Biochemi- formation have been described in mammalian sys- cals, and NADP from Sigma. tems, the “phosphoryl:ted” pathway from 3-phos- Rat cortical tissue was homogenized in 0.32 M phoglycerate [4], and the “non-phosphorylated” sucrose containing 0.5 mM dithiothreitol (DTT) and pathway from D-glycerate [5,6]. We decided there- centrifuged at 105,000 g for 100 min.
    [Show full text]
  • Blueprint Genetics Primary Hyperoxaluria Panel
    Primary Hyperoxaluria Panel Test code: KI0801 Is a 3 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of hyperoxaluria. About Primary Hyperoxaluria The primary hyperoxalurias are rare disorders of glyoxylate metabolism, which result in markedly increased endogenous oxalate synthesis by the liver. They are characterized by an excess of oxalate resulting in manifestations ranging from occasional renal stones, recurrent nephrolithiasis and nephrocalcinosis to end-stage renal disease (ESRD) and systemic oxalosis. Presenting ranges from the neonatal period to adulthood. Among disorders causing hyperoxaluria, the primary hyperoxalurias are the most severe, ultimately leading to ESRD and if untreated, death in most patients. Type I primary hyperoxaluria (PH1), is caused by deficient or absent activity of liver-specific peroxisomal alanine glyoxylate aminotransferase (AGT). In some patients with PH1 type disease, the enzyme is present but mistargeted to mitochondria where it is metabolically inactive. The severe infantile form is characterized by a failure to thrive, nephrocalcinosis with or without nephrolithiasis and early ESRD. Onset in childhood and adolescence is often characterized by recurrent urolithiasis (with or without nephrocalcinosis) and progressive renal failure. The late onset form is characterized by occasional renal stones with onset in adulthood, but acute renal failure caused by bilateral obstruction of the kidneys by oxalate stones may occur. Other manifestations include urinary tract infections, dysuria and hematuria. The ongoing systemic oxalosis also may lead to other clinical manifestations such as cardiac conduction defects, vascular calcification with distal gangrene, disturbed vision, specific brown colored retinal deposits, skin nodules, joint involvement and bone disease leading to fractures in long-term dialysis-dependent patients.
    [Show full text]
  • Grhpr Gene, Full Gene Analysis
    TEST ID: GRHPZ GRHPR GENE, FULL GENE ANALYSIS CLINICAL INFORMATION MOBILE APPS FROM MAYO MEDICAL LABORATORIES Primary hyperoxaluria type 2 (PH2) is a hereditary disorder of glyoxylate metabolism caused by deficiency of the hepatic enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR). Lab Catalog for iPad and Absence of GRHPR activity results in excess oxalate and usually L-glycerate excreted in the Lab Reference for iPhone urine leading to nephrolithiasis (kidney stones) and sometimes renal failure. and iPod Touch Onset of PH2 is typically in childhood or adolescence with symptoms related to kidney stones. In some cases, kidney failure may be the initial presenting feature. Nephrocalcinosis, as seen by renal ultrasound, is observed less frequently in individuals with PH2 than primary Requires iOS 5.1+ hyperoxaluria type 1 (PH1). End-stage renal disease (ESRD) is also less common and of later onset than PH1; however, once ESRD develops, oxalate deposition in other organs such as REFERENCE VALUES bone, retina, and myocardium can occur. An interpretive report will be While the exact prevalence and incidence of PH2 are not known, it is thought that PH2 is less provided. common than PH1, which has an estimated prevalence rate of 1 to 3 per million population and an incidence of 0.1 per million/year. ANALYTIC TIME Biochemical testing is indicated in patients with possible primary hyperoxaluria. Measurement 14 days of urinary oxalate in a timed, 24-hour urine collection is strongly preferred, with correction to adult body surface area in pediatric patients (HYOX / Hyperoxaluria Panel, Urine; OXU / Oxalate, Urine). In very young children (incapable of performing a timed collection), random urine oxalate to creatinine ratios may be used for determination of oxalate excretion.
    [Show full text]
  • Redalyc.The Nutritional Limitations of Plant-Based Beverages in Infancy
    Nutrición Hospitalaria ISSN: 0212-1611 [email protected] Sociedad Española de Nutrición Parenteral y Enteral España Vitoria, Isidro The nutritional limitations of plant-based beverages in infancy and childhood Nutrición Hospitalaria, vol. 34, núm. 5, 2017, pp. 1205-1214 Sociedad Española de Nutrición Parenteral y Enteral Madrid, España Available in: http://www.redalyc.org/articulo.oa?id=309253341026 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Nutr Hosp. 2017; 34(5):1205-1214 ISSN 0212-1611 - CODEN NUHOEQ S.V.R. 318 Nutrición Hospitalaria Revisión The nutritional limitations of plant-based beverages in infancy and childhood Limitaciones nutricionales de las bebidas vegetales en la lactancia y la infancia Isidro Vitoria Unit of Nutrition and Metabolopathies. Hospital Universitario y Politécnico La Fe. Valencia, Spain Abstract Breastfeeding, infant formula and cow’s milk are basic foods in infant nutrition. However, they are being increasingly replaced either totally or partially by plant-based beverages. The composition of 164 plant-based beverages available in Spain was reviewed based on the nutritional labeling of the package and the man- ufacturers’ webpages. This was compared to the composition of cow’s milk and infant formula. In addition, the nutritional disease associated with consumption of plant-based beverages in infants and children was reviewed by means of a literature search in Medline and Embase since 1990 based on the key words “plant-based beverages” or “rice beverages” or “almond beverages” or “soy beverages” and “infant” or “child”.
    [Show full text]